Deal Snapshot: Maze gets $150m up front in cash and equity in exchange for development and commercial rights to a GYS1 program for Pompe disease.
Who: Sanofi and Maze Therapeutics
What: Sanofi gains worldwide development and commercial rights to Maze’s glycogen synthase 1 (GYS1) program, including MZE001, in early clinical...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.
Paying €90m upfront for rights to generalized pustular psoriasis drug.
Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.
IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.
The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.
Paying €90m upfront for rights to generalized pustular psoriasis drug.
In this week's episode: Merck & Co’s Verona acquisition; venture funding plummets in Q2; how Teva is expanding innovation; Apogee’s Phase II eczema win; and a look at India’s wave of licensing.
